A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Neoplasm Metastasis Clinical Trial

Official title:

A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04135352
• Other study ID #: V938-001
• Secondary ID: V938-0012020-003
• Status: Terminated
• Phase: Phase 1
• Start date: November 4, 2019
• Est. completion date: August 24, 2022

Study information

• Verified date: October 2022
• Source: Merck Sharp & Dohme LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and V938 shedding in participants with advanced/metastatic or recurrent malignancies who receive V938 in combination with pembrolizumab (MK-3475). The primary objective is to determine the safety and tolerability and to identify a recommended Phase 2 dose (RP2D) of V938 administered in combination with pembrolizumab.

Description:

Due to discontinuation of V938-001, all ongoing participants who completed V938 plus pembrolizumab treatment may be enrolled in an extension study (KN587) to continue pembrolizumab monotherapy for a total of 35 cycles since the first dose in V938-001 and to be monitored as appropriate.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 35
• Est. completion date: August 24, 2022
• Est. primary completion date: August 24, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• For Dose-escalation arms (Doses A-D): Have a histologically confirmed advanced/metastatic solid tumor and have received, been intolerant to, or been ineligible for treatments known to confer clinical benefit.

• For Dose Expansion Arm A: Have a histologically confirmed Stage III (unresectable) or Stage IV cutaneous melanoma and have received and progressed following 1 or 2 prior lines of systemic treatments for metastatic melanoma which must include 1 line of treatment with PD-1 or PD-L1 immune checkpoint inhibitor either as monotherapy or in combination with other therapy.

• For Dose Expansion Arm B: Have a histologically confirmed advanced head and neck squamous cell carcinoma (HNSCC) and have received and progressed following 1 or 2 prior lines of systemic treatments for metastatic HNSCC which must include 1 line of treatment with PD-1 or PD-L1 immune checkpoint inhibitor either as monotherapy or in combination with other therapy.

• For Dose Expansion Arms A and B: Have at least 1 lesion that is amenable to both intratumoral (IT) injection and biopsy and have at least 1 distant and/or discrete noninjected lesion that is measurable per RECIST 1.1 criteria.

• For Dose-escalation Cohorts 2a, 3a, or 4a and Expansion Cohorts (Arms A and B) ONLY:

Have baseline biopsy performed from 1 of the injectable lesions that are planned for IT injection and with tumor tissue provided.

• For all arms: Have at least 1 cutaneous or subcutaneous lesion amenable to IT injection and must be measurable and meet 1 of the following criteria per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1):

• A cutaneous or subcutaneous lesion =1 cm in longest diameter for solid tumors, or =1.5 cm in short axis for a nodal lesion in participants with solid tumor. The longest diameter for an injectable lesion must be =10 cm for both solid tumors and nodal lesions in participants with solid tumors.

• Multiple coalescing, superficial lesions that in aggregate have a longest diameter of =1 cm and =10 cm.

• Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

• Show adequate organ function.

• Male participants are eligible to participate if they agree to the following during the intervention period and for at least 120 days: either be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR must agree to use contraception unless confirmed to be azoospermic. Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

• Female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:

• Is not a woman of childbearing potential (WOCBP)

• Is a WOCBP and using a contraceptive method that is highly effective, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days after the last dose of study intervention.

• HIV-infected participants must have well controlled HIV on antiretroviral therapy (ART), per study criteria.

Exclusion Criteria:

• Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) prior to the first dose of study intervention or has not recovered from any adverse events (AEs) that were due to cancer therapeutics administered more than 4 weeks earlier. Participants receiving ongoing replacement hormone therapy for endocrine immune-related AEs will not be excluded from participation in this study.

• Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer, or other in-situ cancers.

• Has clinically active central nervous system metastases and/or carcinomatous meningitis.

• Has had a severe hypersensitivity reaction to treatment with the monoclonal antibody/components of the study intervention or has a history of any contraindication or has a severe hypersensitivity to any components of pembrolizumab (=Grade 3).

• Has an active infection requiring therapy.

• Has a history of (noninfectious) pneumonitis that required steroids or current pneumonitis.

• Has an active autoimmune disease that has required systemic treatment in the past 2 years except vitiligo or resolved childhood asthma/atopy.

• Is on chronic systemic steroid therapy in excess of replacement doses (prednisone =10 mg/day is acceptable), or on any other form of immunosuppressive medication.

• Participants with known Hepatitis B or C infections or known to be positive for hepatitis B antigen/hepatitis B virus DNA or hepatitis C antibody or RNA.

• HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.

• Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.

• Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention.

• Has not fully recovered from any effects of major surgery without significant detectable infection.

• Has received a live-virus vaccine within 30 days of planned treatment start.

• Is currently participating and receiving study intervention in a study of an investigational agent or has participated and received study intervention in a study of an investigational agent or has used an investigational device within 28 days of administration of V938.

• Has a history of re-irradiation for HNSCC at the projected injection site.

Related Conditions & MeSH terms

• Neoplasm Metastasis

Intervention

Drug:
• 200 mg of pembrolizumab
Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.

Biological:
• V938
Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre ( Site 0010)	Toronto	Ontario
Israel	Rambam Health Care Campus-Oncology Division ( Site 0020)	Haifa
Israel	Chaim Sheba Medical Center ( Site 0021)	Ramat Gan
United States	MD Anderson Cancer Center ( Site 0001)	Houston	Texas
United States	Huntsman Cancer Institute ( Site 0004)	Salt Lake City	Utah
United States	UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0002)	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Canada,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Experience Dose-Limiting Toxicity (DLT)	The number of participants experiencing toxicities that are possibly, probably, or definitely related to study intervention administration will be reported.	Up to 42 days
Primary	Number of Participants Who Experience =1 Adverse Event (AE)	The number of participants who experience =1 adverse event will be reported.	Up to approximately 28 months
Primary	Number of Participants Who Discontinue Study Drug Due to an Adverse Event (AE)	The number of participants who discontinue study drug due to an adverse event will be reported.	Up to approximately 25 months
Secondary	Objective Response Rate (ORR)	ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions), as assessed by the investigator. In solid tumors, assessment will be based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) and modified RECIST 1.1 for immune-based therapeutics (iRECIST). The percentage of participants who experience a CR or PR based on the above criteria will be presented.	Up to approximately 5 years
Secondary	Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) for V938 Ribonucleic Acid (RNA) in Plasma	The AUC0-inf for V938 RNA in plasma will be calculated.	Predose cycle 1 on 4 separate days, cycles 2, 3, 5, 8, 9, and 10 on day 1. 2, 4, and 6 hours postdose cycle 1 on 2 separate days, and cycle 2 on day 1. 2 to 4 hours postdose cycle 3 on day 1. 30 days after last dose. Each cycle is 21 days.
Secondary	Maximum Concentration (Cmax) of V938 Ribonucleic Acid (RNA) Reached in Plasma	The Cmax for V938 RNA in plasma will be reported.	Predose cycle 1 on 4 separate days, cycles 2, 3, 5, 8, 9, and 10 on day 1. 2, 4, and 6 hours postdose cycle 1 on 2 separate days, and cycle 2 on day 1. 2 to 4 hours postdose cycle 3 on day 1. 30 days after last dose. Each cycle is 21 days.
Secondary	V938 Excretion: Polymerase Chain Reaction (PCR)	The presence of V938, determined by PCR, in oral cavity/throat, urine, injection site, and anus will be reported.	Predose cycle 1 on 3 separate days, and cycles 3, 5, 8, 9, and 10 on day 1. 2 and 4-6 hours postdose cycle 1 day 1. Each cycle is 21 days.
Secondary	V938 Excretion: Infectivity	The presence of V938, determined by infectivity of V938, in oral cavity/throat, urine, injection site, and anus will be reported.	Predose cycle 1 on 3 separate days, and cycles 3, 5, 8, 9, and 10 on day 1. 2 and 4-6 hours postdose cycle 1 day 1. Each cycle is 21 days.

External Links

•   Merck Oncology Clinical Trials Information